Nervous Disorder TRIZ Cases

See how segmented exothermic cells and vapor-air mixing layers sustain water vapor generation w

See how θ-defensin cyclic peptides inhibit TACE enzyme activity to reduce TNF-α release and inf

See how cyclic theta-defensin peptides inhibit TACE enzyme activity to reduce TNF-α release and

See how cyclic theta-defensin peptides inhibit TACE enzyme upstream to reduce TNF-α release, of

See how separating exothermic heat and water vapor sources prevents carbon drying, enabling sus

Layered water-content zones and vapor-air mixing deliver deep moist heat quickly while keeping skin temperature below 43°C.

θ-defensin cyclic peptides inhibit TACE to curb TNF-α-driven inflammation while avoiding the toxicity and broad immunosuppression of existing blockers.

Dew point control and layered heat generation sustain moist heat for deep muscle warming while keeping skin temperature below 43°C.

Polymer-encapsulated catechol magnetic nanoparticle clusters improve bloodstream stability, tumor targeting, and hyperthermic heating.

Combining filtration, UV-C germicidal treatment, and a flexible nose plug purifies inhaled air while maintaining a comfortable nostril seal.

Aromatic-cationic peptides localize to mitochondria to reduce oxidative damage, limit permeability transition, and boost ATP synthesis.

Plant-derived fructose amino acids are extracted and measured to target AGE receptors, reduce inflammation, and support AGE-mediated disease treatment.

HEPA filtration and germicidal UV are combined in a nostril-inserted purifier to reduce particulates, pathogens, and inhalation risk.

Engineered CD3-binding fragments target human and cynomolgus CD3 while reducing effector-driven side effects and improving preclinical relevance.

Isolated plant-derived fructose amino acids target AGE receptors and reduce inflammatory responses in AGE-mediated disease pathways.

Hot rolling above recrystallization followed by warm rolling boosts MMC ductility, prevents cracking, and enables coiled strip processing.

ASGPR-targeting ligands route extracellular proteins into hepatocyte endocytosis and lysosomal degradation, enabling treatment of cytokine- and immunoglobulin-mediated disorders.

ASGPR-targeting ligands recruit extracellular proteins for liver endocytosis and degradation, enabling selective removal of cytokines and immunoglobulins.

Modified ASGPR ligand conjugates recruit extracellular proteins into hepatocytes for endocytosis and lysosomal degradation.

A phosphate honokiol salt improves solubility and bioavailability for parenteral stroke treatment while reducing brain damage without hemorrhagic risk.

By linking an extracellular protein binder to an ASGPR ligand, these conjugates drive hepatocyte uptake and selective clearance of hard-to-drug targets.

Receptor-mediated liver uptake enables selective clearance of extracellular proteins that conventional inhibitors cannot effectively control.

By linking extracellular protein binders to ASGPR ligands, these compounds drive liver uptake and lysosomal degradation of cytokines and immunoglobulins.

Phosphonooxymethyl DMT prodrugs improve metabolic stability and absorption, helping overcome first-pass metabolism and poor oral bioavailability.

Enzyme-cleavable amphetamine prodrugs use GI-triggered release and optional trypsin inhibition to curb misuse, overdose, and peak exposure.

Intranasal delivery of cyclopentapyrrole orexin agonists bypasses the blood-brain barrier to improve CNS access and patient compliance.

Small-molecule ATF6 modulators tune the unfolded protein response to treat cancer, neurodegeneration, and vascular stress with targeted signaling control.

Emulsified cannabis sweeteners make THC water-soluble to improve oral bioavailability, speed onset, and reduce inconsistent metabolism.

Combining xanomeline with trospium chloride raises tolerated muscarinic activation while reducing non-target side effects in schizophrenia treatment.

N-phenyl-1-benzoyl-4-piperidinecarboxamide derivatives inhibit MAGL to address metabolic disorders, neuroinflammation, and cancer.

pH-dependent C2 binders capture complement C2 in circulation, release it in endosomes, and selectively inhibit classical and lectin pathways.

Gene expression profiling predicts which neuronal progenitor cells can engraft and produce dopamine, improving selection for Parkinson's therapy.

Alternating D/L cyclic peptide mimetics improve amyloid beta binding and protease resistance for amyloid disease imaging and treatment.

Engineered anti-IFNAR1 antibodies block IFNα and IFNω signaling while preserving IFNβ-mediated antiviral activity for type I IFN-related diseases.

A swellable gastroretentive bilayer tablet extends lithium carbonate release over 24 hours to support once-daily dosing and steadier serum levels.

Selective heterocyclic KCNT1 inhibitors address gain-of-function channel activity to treat epilepsy and related neurological disorders.

Novel GCN2 modulators enable selective pathway control to improve treatment options for cancer, neurodegeneration, and amino acid stress disorders.

Single-stranded antisense oligonucleotides lower SCN2A expression to treat SCN1A encephalopathies while preserving sodium channel targeting specificity.

Targeted ActRIIB substitutions improve stability, glycosylation consistency, and purification while preserving myostatin and activin inhibition.

Targeted ALCAT1 inhibitors curb harmful cardiolipin remodeling to reduce oxidative stress and mitochondrial dysfunction in age-related disease.

Stabilizing HIF with prolyl hydroxylase inhibitors helps reduce inflammation and support tissue repair in viral lung injury and ARDS.

Selective binding polypeptides target soluble synaptotoxic Aβ oligomers to neutralize toxicity without binding monomeric or fibrillar forms.

Structurally tuned triazinylmethylcycloalkylcarboxylic acids inhibit P2X3 while sparing P2X2/3, improving selectivity for pain and bladder therapy.

Lower-dose FENM combined with an acetylcholinesterase inhibitor improves cognitive benefit while reducing adverse effects in neurodegenerative treatment.

Combining an IDH1-targeting compound with radiation helps treat gliomas while limiting resistance and improving survival outcomes.

Highly purified CBDV with low THC offers canine seizure control when standard anti-epileptic drugs have limited efficacy or cause side effects.

Selective 2-aminoquinazoline LRRK2 inhibitors address inadequate kinase targeting in Parkinson's disease while aiming to limit off-target effects.

Novel dihydrooxazole and thiourea derivatives selectively inhibit NLRP3 activation to lower IL-1 beta and IL-18 with improved potency and bioavailability.

Carboxylic acid indanyl compounds selectively modulate S1P5 to expand treatment options for neurodegenerative diseases such as Alzheimer's and multiple sclerosis.

Iron-loaded stem cell nanovesicles improve intravenous targeting with magnetic guidance while overcoming low exosome yield and direct injection limits.

Bifunctional indazole PROTACs degrade IRAK4 to address mutation-driven resistance while balancing pharmacokinetic constraints.

Selective SUV39H1 inhibitor ETP69 lowers hippocampal H3K9me3 to improve learning, memory, and age-related cognitive deficits.

Substituted fused gamma-carbolines target 5-HT2 receptors and normalize dopamine activity to improve PTSD and impulse control treatment outcomes.

Humanized anti-ST2 antibodies improve binding affinity and stability to block IL-33 signaling and reduce inflammatory cytokine production.

Targeting IL-33 alone or with IL-4 blockade reduces inflammatory markers and exacerbations in lung disease while limiting corticosteroid side effects.

Organic-cation amorphous folate salts improve solubility in water and apolar solvents while maintaining stability for flexible drug formulations.

Non-covalent BTK inhibitors overcome C481 mutation resistance while lowering off-target toxicity and improving blood-brain barrier penetration.

Sheep-derived anti-tau antibodies target key tau epitopes with high affinity, improving detection and inhibition of tau aggregation.

Using IGF1R-mediated transcytosis, a bispecific antibody crosses the blood-brain barrier to deliver alpha-synuclein therapy without disrupting BBB physiology.

Specific fused gamma-carbolines target 5-HT2 receptors to improve PTSD and impulse control disorder treatment, alone or with antidepressants.

A cooling-agent alcohol composition activates parasympathetic signaling to improve sleep, immunity, liver regeneration, and vascular protection.

Targets the acetylated S565 site on COX2 to measure reduced acetylation linked to neurodegenerative and inflammatory diseases.

Highly purified or synthetic CBD treats Angelman syndrome symptoms such as anxiety, ataxia, and cognitive dysfunction with fewer side effects.

A bilayer donepezil oral film keeps the drug crystalline for storage stability while masking bitterness and dispersing quickly without water.

Small molecules modulate pre-mRNA splicing while avoiding oligonucleotide limits in oral delivery, BBB penetration, and cellular access.

A gel scaffold with a CCR5 antagonist helps transplanted neural precursor cells survive inflammation and differentiate at brain lesion sites.

Combining tryptamines with Hericium-derived erinacines and hericenones promotes neurite growth while supporting cognition and neurodegenerative care.

Carbonyl-linked oleic acid derivatives curb lipid peroxidation and ferroptosis while improving clearance duration for Friedreich ataxia treatment.

Codon-optimized UBE3A cassettes and vectors enable dual-isoform expression to rescue Angelman syndrome phenotypes despite delivery complexity.

Compact AAV gene cassettes restore AP-4 subunit expression in neurons, addressing payload limits while targeting AP-4-HSP.

Specific miRNAs such as miR-425-5p improve mild TBI diagnosis and recovery monitoring when protein biomarkers lack sensitivity and specificity.

Infrared sensing tracks nozzle movement and vial insertion to verify authorized nasal spray dosing while reducing misuse and theft.

Targeted pyrimidin-4(3H)-one TRPV4 antagonists improve efficacy while lowering toxicity, QT prolongation risk, and drug interactions.

A peptide-based approach targets 4R tau hyperphosphorylation and aggregation while avoiding the cytotoxicity seen with earlier inhibitors.

Paired xanomeline and trospium beads improve muscarinic receptor therapy tolerability while preserving efficacy for cognitive and psychotic disorders.

Bispecific NKG2D-CD3 and NKG2D-CD16 engagers bridge senescent cells and immune cells to improve clearance while reducing toxic side effects.

Combining an aromatase inhibitor with antioxidants such as α-lipoic acid helps suppress tumor growth while reducing oxidative stress and side effects.

Selective Grp94 allosteric inhibitors overcome pan-Hsp90 cross-binding, avoid heat shock feedback, and promote apoptosis in cancer cells.

A four-herb water extract addresses limited Alzheimer's therapies by improving cognition, easing symptoms, and reducing beta-amyloid plaques.

Antigen-sensitized dead immature dendritic cells enable earlier immune response while avoiding the cost and complexity of mature live-cell vaccines.

Peripheral anti-CGRP antibodies unexpectedly accumulate in the brain to reduce chemotherapy-induced nausea and vomiting.

Dual-route rAAV.FXN delivery raises frataxin levels to stabilize neurological symptoms and slow cardiomyopathy in Friedreich's ataxia.

A micronutrient blend activates CBS and CSE to raise H2S where needed, avoiding the imprecise release pattern of exogenous donors.

Sequentially increasing anti-amyloid antibody doses lowers cerebral amyloid burden while reducing ARIA risk, including ARIA-E and ARIA-H.

Combined fungal, plant, and algae bioactives target motor and non-motor symptoms while aiming to slow or reverse Parkinson's progression.

A crystalline hydrochloride trihydrate form improves stability and bioavailability of a T-type calcium channel blocker for neurological disorders.

A nitrogen-containing heterocycle boosts M1 receptor activity through allosteric binding, improving selectivity for CNS disorder treatment.

A single rAAV vector co-delivers PGRN and STMN2 to address both loss- and gain-of-function TDP-43 mechanisms in CNS proteinopathies.

Selective heterocyclic S1P receptor modulators improve treatment options for multiple sclerosis, ulcerative colitis, and Crohn's disease.

Targeted endoscopic neurotoxin injections in the pylorus and stomach improve gastric emptying and reduce gastroparesis symptoms with more consistent relief.

A 14-3-3θ-derived peptide clears pathological TDP-43 and reduces ALS and FTD symptoms linked to cytoplasmic accumulation.

Cyclodextrin and PEG stimulate hippocampal neural precursors to boost adult neurogenesis, improving memory and reducing allodynia.

A GABA-producing Lactobacillus brevis strain improves gut microbial diversity, insulin sensitivity, and adipose reduction in metabolic disorders.

An active site-specific chaperone keeps high-concentration rhGAA stable, limits aggregation, and improves tissue uptake for Pompe disease treatment.

A PEG400-based NTSR1 agonist formulation slows absorption to treat autism sensory deficits without the lethargy seen at higher doses.

Modified 2C-B, methylone, and MBDB regimens aim to preserve fast antidepressant effects while reducing side effects and drug interactions.

Bispecific TNF receptor agonists engage CD40, CD27, OX40, or 4-1BB to boost immune signaling through IL-8 release and NF-κB activation.

Human trophoblast-derived neural stem cells differentiate into functional neurons to improve sensorimotor function in neurodegenerative disorders.

Patient-specific iPSC-derived mDA progenitor cells restore dopamine function while avoiding the side effects of conventional Parkinson's drugs.

A monoamine reuptake inhibitor linked to an HDAC inhibitor improves antidepressant response while reducing side effects and onset delay.

An oral ASD composition combines antivirals, probiotics, selenium, and omega-3s to support immune, digestive, and cognitive function.

Subepithelial umbilical cord cells are isolated and expanded to enable allogeneic therapy with reduced immune rejection and broad differentiation potential.

rAAV delivery of codon-optimized CLN2 enables sustained CNS TPP1 activity, reducing frequent Brineura infusions and patient burden.

Targeting low TPK activity, this case shows how a TPK agonist restores cerebral glucose metabolism for Alzheimer's prophylaxis and treatment.

Manganese supplementation boosts mtDNA synthesis in cells with impaired ER-mitochondria contact sites, enabling targeted neurodegenerative therapy.

Solid salt and polymorph forms of MDMA-related phenethylamines improve stability, solubility, and bioavailability for neuropsychiatric treatment.

A four-compound supplement raises NAC, glycine, choline, and biotin to effective levels for synergistic neuroprotection and cognitive support.

Low-dose topiramate with immediate-release phentermine maintains weight loss efficacy while reducing side effects in obesity treatment.

Pre-treatment PD-L1 biomarker testing helps identify likely responders to PD-1/PD-L1 antagonists and supports better therapy selection in cancer.

Tetrahydroquinoline derivatives use substituent tuning to improve ferroptosis inhibition and support treatment of multiple sclerosis.

RFX1 and RFX3 combined with ATOH1 drive hiPSCs into mature hair cell-like cells, improving hearing-loss cell replacement without coculture contamination.

rAAV9 delivers functional CLN3 to CNS cells to reduce storage buildup, slow neuroinflammation, and delay CLN3-Batten disease progression.

Selective capture on solid supports detects surface and adsorbed exosome biomarkers without lysis, improving routine disease diagnosis accuracy.

AAV8/AAV9 vectors deliver TERT and Klotho to the CNS via intranasal or intrathecal routes, improving cognitive scores with low toxicity.

Selective κ-opioid agonist peptides boost analgesic and antipruritic activity while avoiding μ-opioid side effects such as dependence and respiratory depression.

Balanced THC:CBD ratios with selected terpenes relieve chronic pain while cutting opioid intake by at least 50% within 5 weeks.

Controlled polymer degradation and diffusion help flexible implantable depots avoid burst release and sustain localized analgesic delivery.

Novel bicyclic pyridine derivatives activate TAAR1 while limiting other GPCR and hERG effects, supporting safer antipsychotic and antidepressant therapy.

Crosslinked low-endotoxin alginate enables non-tubular nerve repair for branches and plexus defects with suturable, absorbable support.

Small-molecule urea derivatives inhibit hyperactive NLRP3 to preserve immune defense while limiting chronic inflammation and tissue damage.

Heterobifunctional degraders recruit VHL or cereblon ligases to break down many kinases, helping identify targets in drug-resistant cells.

Concomitant CBD and psilocybin dosing targets neuroinflammation, neurogenesis, and anxiety symptoms in TBI and PTSD treatment.

Guide RNA targeting replaces custom nuclease design while improving precise cleavage, homology-directed repair, and base editing in eukaryotic cells.

PEG-based extraction converts olive oleacein and oleomissional into pure, soluble diol forms without chromatography for pharmaceutical use.

AAV-delivered miRNAs selectively silence mutant KCNQ3 transcripts to reduce seizures and disease features in DEE models.

A 4-aminopyrrolotriazine scaffold is tuned to inhibit DYRK1A, reducing cancer cell proliferation and attenuating neurodegeneration.

Muscle-specific AAV delivery restores BVES expression to improve muscle mass and function while reducing heart rhythm abnormalities.